Efficacy of a Paclitaxel-Eluting Nitinol Stent on the Inhibition of Pseudointimal Hyperplasia in a Transjugular Intrahepatic Portosystemic Shunt: An Experimental Study in a Swine Model.
10.3348/jkrs.2007.56.3.225
- Author:
Tae Seok SEO
1
;
Joo Hyeong OH
;
Se Hwan KWON
;
Young Koo PARK
;
Ho Young SONG
;
Sun Hong YUK
Author Information
1. Department of Diagnostic Radiology, Kyung Hee University Hospital, Seoul, Korea. ohjh6108@hanmail.net
- Publication Type:Original Article
- Keywords:
Interventional procedures, experimental studies;
Shunts, portosystemic;
Stents and prostheses;
Drugs
- MeSH:
Animals;
Follow-Up Studies;
Hyperplasia*;
Paclitaxel;
Polyurethanes;
Portasystemic Shunt, Surgical*;
Radius;
Stents*;
Swine*
- From:Journal of the Korean Radiological Society
2007;56(3):225-232
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To evaluate the efficacy of a paclitaxel-eluting nitinol stent on the inhibition of pseudointimal hyperplasia in a transjugular intrahepatic portosystemic shunt. MATERIALS AND METHODS: Twelve pigs were used in this study. Two types of 10-mm diameter and 60-mm long nitinol stents were made for a transjugular intrahepatic portosystemic shunt by coating them with a polyurethane solution, with and without paclitaxel. Each transjugular intrahepatic portosystemic shunt was created successfully in the 12 swine with 7 paclitaxel-eluting stents and 5 polyurethane stents. Five swine in each group were followed-up for 14 days due to the death of 2 swine given the paclitaxel-eluting stents. The proliferation of the pseudointima was evaluated on both follow-up portograms and histopathology examinations. The mean maximum pseudointimal hyperplasia is expressed as the percentage of the stent radius. RESULTS: On the portograms, all the transjugular intrahepatic portosystemic shunts using the paclitaxel-eluting stents maintained patency despite there being a complete occlusion of the polyurethane stents in all the animals. The histopathology analysis revealed the mean maximum pseudointimal hyperplasia to be 25% and 76% in the paclitaxel-eluting and control stents, respectively. CONCLUSION: A transjugular intrahepatic portosystemic shunt with a paclitaxel-eluting nitinol stent appears to significantly inhibit the formation of pseudointimal hyperplasia.
